Stay updated on Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Sign up to get notified when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.

Latest updates to the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page
- Check6 days agoChange DetectedA new site revision entry v3.4.3 was added and v3.4.2 was removed.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedA minor site revision (v3.4.2) was added; the non-critical funding-status notice and a prior revision notice (v3.4.1) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check41 days agoChange DetectedA site-wide notice about a lapse in government funding was added, warning that information may not be up to date and that transactions may not be processed, with a link to opm.gov. The page revision label was updated to v3.4.1 (removing v3.4.0).SummaryDifference0.3%

- Check48 days agoChange DetectedShow glossary added; QC-related 'Last Update Submitted that Met QC Criteria' field added; No FEAR Act Data disclosure added; page revision updated to v3.4.0. Previously shown items 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and revision v3.3.4 were removed.SummaryDifference0.1%

- Check84 days agoChange DetectedThe page's Locations section was reorganized to enumerate site locations by state (Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Michigan, Mississippi, Missouri, Nebraska, New Mexico, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington) and a new Revision: v3.3.3 tag appears; individual state-location entries were removed, and the HHS Vulnerability Disclosure link was deleted.SummaryDifference1%

- Check106 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; it appears to be a minor site version update with no changes to the study details or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.